{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:31:10Z","timestamp":1757619070403,"version":"3.44.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s00108-025-01949-7","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T15:29:31Z","timestamp":1752593371000},"page":"785-792","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CAR-T-Zell-Therapie bei der akuten lymphoblastischen Leuk\u00e4mie","CAR T cell therapy in acute lymphoblastic leukemia"],"prefix":"10.1007","volume":"66","author":[{"given":"Manik","family":"Chatterjee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf C.","family":"Bargou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"1949_CR1","doi-asserted-by":"crossref","unstructured":"Ray A, Levitt M, Efunkoya T et al. (2024) Precision Medicine for Acute Lymphoblastic Leukemia in Children: A Review. Children (Basel) 11","DOI":"10.20944\/preprints202410.0191.v1"},{"key":"1949_CR2","doi-asserted-by":"crossref","unstructured":"Sucre O, Pamulapati S, Muzammil Z et al. (2025) Advances in Therapy of Adult Patients with Acute Lymphoblastic Leukemia. Cells 14","DOI":"10.3390\/cells14050371"},{"key":"1949_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13045-023-01409-5","volume":"16","author":"E Jabbour","year":"2023","unstructured":"Jabbour E, Short NJ, Jain N et al. (2023) The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades. J Hematol Oncol 16:22","journal-title":"J Hematol Oncol"},{"key":"1949_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40164-022-00368-w","volume":"12","author":"D Caracciolo","year":"2023","unstructured":"Caracciolo D, Mancuso A, Polera N et al. (2023) The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives. Exp Hematol Oncol 12:5","journal-title":"Exp Hematol Oncol"},{"key":"1949_CR5","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1016\/S0140-6736(12)62187-4","volume":"381","author":"H Inaba","year":"2013","unstructured":"Inaba H, Greaves M, Mullighan CG (2013) Acute lymphoblastic leukaemia. Lancet 381:1943\u20131955","journal-title":"Lancet"},{"key":"1949_CR6","doi-asserted-by":"crossref","unstructured":"Kantarjian H, Jabbour E (2025) Adult Acute Lymphoblastic Leukemia: 2025 Update on Diagnosis, Therapy, and Monitoring. Am J Hematol","DOI":"10.1002\/ajh.27708"},{"key":"1949_CR7","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1007\/s11912-024-01608-4","volume":"26","author":"S Elgazar","year":"2024","unstructured":"Elgazar S, Constantinou C (2024) Paediatric Acute Lymphoblastic Leukaemia: A Narrative Review of Current Knowledge and Advancements. Curr Oncol Rep 26:1586\u20131599","journal-title":"Curr Oncol Rep"},{"key":"1949_CR8","doi-asserted-by":"crossref","unstructured":"Iacobucci I, Kimura S, Mullighan CG (2021) Biologic and Therapeutic Implications of Genomic Alterations in Acute Lymphoblastic Leukemia. J Clin Med 10","DOI":"10.3390\/jcm10173792"},{"key":"1949_CR9","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","volume":"131","author":"N Gokbuget","year":"2018","unstructured":"Gokbuget N, Dombret H, Bonifacio M et al. (2018) Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood 131:1522\u20131531","journal-title":"Blood"},{"key":"1949_CR10","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1200\/JCO.21.01766","volume":"40","author":"AS Advani","year":"2022","unstructured":"Advani AS, Moseley A, O\u2019Dwyer KM et al. (2022) SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. J Clin Oncol 40:1574\u20131582","journal-title":"J Clin Oncol"},{"key":"1949_CR11","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa2312948","volume":"391","author":"MR Litzow","year":"2024","unstructured":"Litzow MR, Sun Z, Mattison RJ et al. (2024) Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults. N Engl J Med 391:320\u2013333","journal-title":"N Engl J Med"},{"key":"1949_CR12","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J et al. (2018) Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med 378:439\u2013448","journal-title":"N Engl J Med"},{"key":"1949_CR13","doi-asserted-by":"publisher","first-page":"2335856","DOI":"10.1080\/16078454.2024.2335856","volume":"29","author":"ZY Xiong","year":"2024","unstructured":"Xiong ZY, Shen YJ, Zhang SZ et al. (2024) A review of immunotargeted therapy for Philadelphia chromosome positive acute lymphoblastic leukaemia: making progress in chemotherapy-free regimens. Hematology 29:2335856","journal-title":"Hematology"},{"key":"1949_CR14","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1182\/blood-2015-02-629527","volume":"126","author":"M Mamonkin","year":"2015","unstructured":"Mamonkin M, Rouce RH, Tashiro H et al. (2015) A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood 126:983\u2013992","journal-title":"Blood"},{"key":"1949_CR15","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jcyt.2022.08.010","volume":"25","author":"KS Peggs","year":"2023","unstructured":"Peggs KS, Albon SJ, Oporto Espuelas M et al. (2023) Immunotherapy with CD25\/CD71-allodepleted T cells to improve T-cell reconstitution after matched unrelated donor hematopoietic stem cell transplant: a randomized trial. Cytotherapy 25:82\u201393","journal-title":"Cytotherapy"},{"key":"1949_CR16","doi-asserted-by":"publisher","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","volume":"86","author":"G Gross","year":"1989","unstructured":"Gross G, Waks T, Eshhar Z (1989) Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A 86:10024\u201310028","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1949_CR17","doi-asserted-by":"publisher","first-page":"104","DOI":"10.4049\/jimmunol.172.1.104","volume":"172","author":"HM Finney","year":"2004","unstructured":"Finney HM, Akbar AN, Lawson AD (2004) Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol 172:104\u2013113","journal-title":"J Immunol"},{"key":"1949_CR18","doi-asserted-by":"publisher","first-page":"10995","DOI":"10.1158\/0008-5472.CAN-06-0160","volume":"66","author":"CM Kowolik","year":"2006","unstructured":"Kowolik CM, Topp MS, Gonzalez S et al. (2006) CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 66:10995\u201311004","journal-title":"Cancer Res"},{"key":"1949_CR19","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1073\/pnas.0813101106","volume":"106","author":"C Carpenito","year":"2009","unstructured":"Carpenito C, Milone MC, Hassan R et al. (2009) Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A 106:3360\u20133365","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1949_CR20","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1158\/0008-5472.CAN-11-0103","volume":"71","author":"M Chmielewski","year":"2011","unstructured":"Chmielewski M, Kopecky C, Hombach AA et al. (2011) IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res 71:5697\u20135706","journal-title":"Cancer Res"},{"key":"1949_CR21","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nm.4478","volume":"24","author":"Y Kagoya","year":"2018","unstructured":"Kagoya Y, Tanaka S, Guo T et al. (2018) A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. Nat Med 24:352\u2013359","journal-title":"Nat Med"},{"key":"1949_CR22","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1200\/JCO.22.00642","volume":"41","author":"TW Laetsch","year":"2023","unstructured":"Laetsch TW, Maude SL, Rives S et al. (2023) Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed\/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial. J Clin Oncol 41:1664\u20131669","journal-title":"J Clin Oncol"},{"key":"1949_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood.2020009098","volume":"138","author":"BD Shah","year":"2021","unstructured":"Shah BD, Bishop MR, Oluwole OO et al. (2021) KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed\/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood 138:11\u201322","journal-title":"Blood"},{"key":"1949_CR24","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1038\/s41375-025-02532-7","volume":"39","author":"BD Shah","year":"2025","unstructured":"Shah BD, Cassaday RD, Park JH et al. (2025) Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. Leukemia 39:1058\u20131068","journal-title":"Leukemia"},{"key":"1949_CR25","doi-asserted-by":"publisher","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","volume":"4","author":"MC Pasquini","year":"2020","unstructured":"Pasquini MC, Hu ZH, Curran K et al. (2020) Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv 4:5414\u20135424","journal-title":"Blood Adv"},{"key":"1949_CR26","doi-asserted-by":"publisher","first-page":"5493","DOI":"10.1182\/bloodadvances.2024013962","volume":"8","author":"F Rabian","year":"2024","unstructured":"Rabian F, Beauvais D, Marchand T et al. (2024) Efficacy and tolerance of brexucabtagene autoleucel in adults with R\/R B-ALL: a GRAALL study from the DESCAR-T registry. Blood Adv 8:5493\u20135496","journal-title":"Blood Adv"},{"key":"1949_CR27","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41417-023-00593-3","volume":"30","author":"M Elsallab","year":"2023","unstructured":"Elsallab M, Ellithi M, Hempel S et al. (2023) Long-term response to autologous anti-CD19 chimeric antigen receptor T cells in relapsed or refractory B cell acute lymphoblastic leukemia: a systematic review and meta-analysis. Cancer Gene Ther 30:845\u2013854","journal-title":"Cancer Gene Ther"},{"key":"1949_CR28","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P et al. (2018) Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol 15:47\u201362","journal-title":"Nat Rev Clin Oncol"},{"key":"1949_CR29","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3324\/haematol.2019.229781","volume":"105","author":"I Yakoub-Agha","year":"2020","unstructured":"Yakoub-Agha I, Chabannon C, Bader P et al. (2020) Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica 105:297\u2013316","journal-title":"Haematologica"},{"key":"1949_CR30","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","volume":"5","author":"E Sotillo","year":"2015","unstructured":"Sotillo E, Barrett DM, Black KL et al. (2015) Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discov 5:1282\u20131295","journal-title":"Cancer Discov"},{"key":"1949_CR31","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","volume":"24","author":"EJ Orlando","year":"2018","unstructured":"Orlando EJ, Han X, Tribouley C et al. (2018) Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med 24:1504\u20131506","journal-title":"Nat Med"},{"key":"1949_CR32","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","volume":"127","author":"R Gardner","year":"2016","unstructured":"Gardner R, Wu D, Cherian S et al. (2016) Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood 127:2406\u20132410","journal-title":"Blood"},{"key":"1949_CR33","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1186\/s12885-022-09489-1","volume":"22","author":"L An","year":"2022","unstructured":"An L, Lin Y, Deng B et al. (2022) Humanized CD19 CAR-T cells in relapsed\/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy. BMC Cancer 22:393","journal-title":"BMC Cancer"},{"key":"1949_CR34","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN (2023) Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol 20:359\u2013371","journal-title":"Nat Rev Clin Oncol"},{"key":"1949_CR35","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/s41573-023-00807-1","volume":"22","author":"M Ruella","year":"2023","unstructured":"Ruella M, Korell F, Porazzi P et al. (2023) Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies. Nat Rev Drug Discov 22:976\u2013995","journal-title":"Nat Rev Drug Discov"},{"key":"1949_CR36","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1111\/febs.17326","volume":"292","author":"Y Sun","year":"2025","unstructured":"Sun Y, Liu J, Zhan D et al. (2025) Depletion of Tregs from CD4(+) CAR-T cells enhances the tumoricidal effect of CD8(+) CAR-T cells in anti-CD19 CAR-T therapy. FEBS J 292:1904\u20131919","journal-title":"FEBS J"},{"key":"1949_CR37","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1126\/science.1158545","volume":"321","author":"R Bargou","year":"2008","unstructured":"Bargou R, Leo E, Zugmaier G et al. (2008) Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321:974\u2013977","journal-title":"Science"},{"key":"1949_CR38","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1182\/bloodadvances.2019000457","volume":"3","author":"N Gokbuget","year":"2019","unstructured":"Gokbuget N, Kantarjian HM, Bruggemann M et al. (2019) Molecular response with blinatumomab in relapsed\/refractory B-cell precursor acute lymphoblastic leukemia. Blood Adv 3:3033\u20133037","journal-title":"Blood Adv"},{"key":"1949_CR39","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, Gokbuget N et al. (2017) Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med 376:836\u2013847","journal-title":"N Engl J Med"},{"key":"1949_CR40","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ymthe.2022.09.003","volume":"31","author":"N Watanabe","year":"2023","unstructured":"Watanabe N, Mo F, Zheng R et al. (2023) Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies. Mol Ther 31:24\u201334","journal-title":"Mol Ther"},{"key":"1949_CR41","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3324\/haematol.2019.233882","volume":"106","author":"V Wiebking","year":"2021","unstructured":"Wiebking V, Lee CM, Mostrel N et al. (2021) Genome editing of donor-derived T-cells to generate allogenic chimeric antigen receptor-modified T cells: Optimizing alphabeta T cell-depleted haploidentical hematopoietic stem cell transplantation. Haematologica 106:847\u2013858","journal-title":"Haematologica"},{"key":"1949_CR42","doi-asserted-by":"crossref","unstructured":"Hegde M, Mukherjee M, Grada Z et al. (2021) Tandem CAR T cells targeting HER2 and IL13Ralpha2 mitigate tumor antigen escape. J Clin Invest 131","DOI":"10.1172\/JCI152477"},{"key":"1949_CR43","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1182\/blood.2022015795","volume":"140","author":"H Shalabi","year":"2022","unstructured":"Shalabi H, Qin H, Su A et al. (2022) CD19\/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR. Blood 140:451\u2013463","journal-title":"Blood"},{"key":"1949_CR44","doi-asserted-by":"publisher","first-page":"aab4077","DOI":"10.1126\/science.aab4077","volume":"350","author":"CY Wu","year":"2015","unstructured":"Wu CY, Roybal KT, Puchner EM et al. (2015) Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science 350:aab4077","journal-title":"Science"},{"key":"1949_CR45","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","volume":"365","author":"A Di Stasi","year":"2011","unstructured":"Di Stasi A, Tey SK, Dotti G et al. (2011) Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 365:1673\u20131683","journal-title":"N Engl J Med"},{"key":"1949_CR46","doi-asserted-by":"crossref","unstructured":"Qasim W, Zhan H, Samarasinghe S et al. (2017) Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med 9","DOI":"10.1126\/scitranslmed.aaj2013"},{"key":"1949_CR47","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","volume":"391","author":"C Roddie","year":"2024","unstructured":"Roddie C, Sandhu KS, Tholouli E et al. (2024) Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia. N Engl J Med 391:2219\u20132230","journal-title":"N Engl J Med"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-025-01949-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-025-01949-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-025-01949-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T12:41:39Z","timestamp":1757248899000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-025-01949-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1949"],"URL":"https:\/\/doi.org\/10.1007\/s00108-025-01949-7","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"type":"print","value":"2731-7080"},{"type":"electronic","value":"2731-7099"}],"subject":[],"published":{"date-parts":[[2025,7,15]]},"assertion":[{"value":"18 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"R.C.\u00a0Bargou h\u00e4lt das Patent f\u00fcr Blinatumomab, f\u00fcr das er Lizenzgeb\u00fchren erh\u00e4lt. R.C.\u00a0Bargou hat Honorare f\u00fcr seine T\u00e4tigkeit in den Beratungsgremien von Amgen, Bristol-Myers Squibb, Gemoab, Novartis und Roche erhalten. M. Chatterjee gibt an, dass kein Interessenskonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}